<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37031468</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1983</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Clinical nutrition (Edinburgh, Scotland)</Title><ISOAbbreviation>Clin Nutr</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of probiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis of randomised clinical trials using ROME IV criteria.</ArticleTitle><Pagination><StartPage>800</StartPage><EndPage>809</EndPage><MedlinePgn>800-809</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clnu.2023.03.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0261-5614(23)00100-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder which affects a great number of patients globally. Clinical trials and meta-analyses have evaluated different therapies for IBS. Some of them have shown that probiotics play a significant role in the management of IBS-patients. Nevertheless, results are controversial, and the efficacy of the administration of probiotics remains to be confirmed, especially in regard to which type of probiotic-strains are beneficial.</AbstractText><AbstractText Label="AIM">The aim of the present meta-analysis is to assess the efficacy and safety of the administration of probiotics to IBS-patients with a diagnosis based on Rome IV criteria, which is performed for the first time.</AbstractText><AbstractText Label="METHODS">Electronic databases (Pubmed, Scopus and Cochrane) were searched until 26.01.2023 for randomized controlled trials (RCTs) studying the administration of probiotics in adult IBS-patients, who were categorized according to the Rome IV criteria. The risk of bias was assessed using the Cochrane Risk of Bias tool (ROB) 2.0. Weighted and standardized mean difference with the 95% confidence intervals were used for the synthesis of the results. Primary outcomes were the decrease of IBS-Symptom Severity Score (IBS-SSS) and decrease of abdominal pain. The secondary outcomes were the improvement in quality of life (QoL) and the decrease of bloating. Lastly, the adverse effects of probiotics were evaluated. The protocol of the study has been registered at protocols.io (DOI dx.doi.org/10.17504/protocols.io.14egn218yg5d/v1).</AbstractText><AbstractText Label="RESULTS">Six double-blind (N&#xa0;=&#xa0;970) placebo-control RCTs fulfilled the inclusion criteria and overall, nine different strains of probiotics were examined. No significant reduction in IBS-SSS (WMD&#xa0;-43.2, 95% CI&#xa0;-87.5 to 1.0, I<sup>2</sup>&#xa0;=&#xa0;82.9%) was demonstrated, whereas a significant decrease regarding abdominal pain (SMD&#xa0;-0.94, 95% CI&#xa0;-1.53 to&#xa0;-0.35, I<sup>2</sup>&#xa0;=&#xa0;92,2) was shown. Furthermore, no correlation between improvement of QoL and the use of probiotics (SMD&#xa0;-0.64, 95% CI&#xa0;-1.27 to 0.00, I<sup>2</sup>&#xa0;= 93,9%) was shown. However, probiotics were associated with a significant reduction in bloating (SMD&#xa0;-0.28, 95% CI&#xa0;-0.47 to&#xa0;-0.09, I<sup>2</sup>&#xa0;= 36,0%). A qualitative synthesis was conducted about adverse events and showed that the use of probiotics' is safe without severe adverse events.</AbstractText><AbstractText Label="CONCLUSIONS">The administration of probiotics to IBS-patients demonstrated a positive effect on pain and bloating, but due to significant heterogeneity and confounding factors, that were not examined in the included studies, a definitive statement cannot be made. Moreover, probiotics did not lead to an improvement in other parameters. There is a need for larger RCTs in IBS-patients diagnosed according to Rome IV (not III) criteria and especially it is essential to be conducted RCTs which examine the administration of specific strains and have similar methodological characteristics.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Konstantis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Efstathiou</LastName><ForeName>Stylianos</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pourzitaki</LastName><ForeName>Chryssa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. Electronic address: chpour@auth.gr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitsikidou</LastName><ForeName>Elisavet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Evangelical Hospital Dusseldorf, Dusseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Germanidis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, 1st Department of Internal Medicine, AHEPA University Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chourdakis</LastName><ForeName>Michail</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Hygiene, Social &amp; Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Nutr</MedlineTA><NlmUniqueID>8309603</NlmUniqueID><ISSNLinking>0261-5614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal pain</Keyword><Keyword MajorTopicYN="N">Bloating</Keyword><Keyword MajorTopicYN="N">IBS-SSS</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword><Keyword MajorTopicYN="N">Rome IV</Keyword></KeywordList><CoiStatement>Conflict of interest None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>9</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37031468</ArticleId><ArticleId IdType="doi">10.1016/j.clnu.2023.03.019</ArticleId><ArticleId IdType="pii">S0261-5614(23)00100-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>